Charles Schwab
HRMY icon

Charles Schwab’s Harmony Biosciences HRMY Stock Holding History

Charles Schwab’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.4M Buy
423,824
+12,227
+3% +$386K ﹤0.01% 1951
2026
Q1 		$11.5M Sell
411,597
-6,358
-2% -$208K ﹤0.01% 2036
2025
Q4 		$15.6M Sell
417,955
-38,446
-8% -$1.26M ﹤0.01% 1901
2025
Q3 		$12.6M Buy
456,401
+18,560
+4% +$639K ﹤0.01% 2004
2025
Q2 		$13.8M Sell
437,841
-28,231
-6% -$908K ﹤0.01% 1849
2025
Q1 		$15.5M Sell
466,072
-5,956
-1% -$214K ﹤0.01% 1753
2024
Q4 		$16.2M Buy
472,028
+100,586
+27% +$3.46M ﹤0.01% 1801
2024
Q3 		$14.9M Sell
371,442
-3,266
-0.9% -$115K ﹤0.01% 1854
2024
Q2 		$11.3M Buy
374,708
+1,192
+0.3% +$35.8K ﹤0.01% 1984
2024
Q1 		$12.5M Buy
373,516
+54,349
+17% +$1.74M ﹤0.01% 1870
2023
Q4 		$10.3M Buy
319,167
+28,256
+10% +$789K ﹤0.01% 1968
2023
Q3 		$9.53M Buy
290,911
+42,736
+17% +$1.48M ﹤0.01% 1930
2023
Q2 		$8.73M Buy
248,175
+24,266
+11% +$838K ﹤0.01% 1968
2023
Q1 		$7.31M Sell
223,909
-1,783
-0.8% -$81.2K ﹤0.01% 2023
2022
Q4 		$12.4M Sell
225,692
-30,014
-12% -$1.65M ﹤0.01% 1729
2022
Q3 		$11.3M Buy
255,706
+20,382
+9% +$994K ﹤0.01% 1769
2022
Q2 		$11.5M Sell
235,324
-25,067
-10% -$1.13M ﹤0.01% 1768
2022
Q1 		$12.7M Sell
260,391
-6,658
-2% -$272K ﹤0.01% 1820
2021
Q4 		$11.4M Buy
267,049
+35,020
+15% +$1.4M ﹤0.01% 1938
2021
Q3 		$8.89M Buy
232,029
+184,652
+390% +$5.95M ﹤0.01% 2077
2021
Q2 		$1.34M Buy
47,377
+33,610
+244% +$1.01M ﹤0.01% 2833
2021
Q1 		$455K Buy
13,767
+821
+6% +$28.8K ﹤0.01% 3111
2020
Q4 		$468K Buy
+12,946
New +$523K ﹤0.01% 3011

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab's HRMY Position: Q2 2026 in Review

Charles Schwab increased its Harmony Biosciences (HRMY) stake by 3% in Q2 2026, buying an estimated $386K and bringing the position to 423,824 shares worth $15.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1951.

Charles Schwab first reported a position in HRMY in Q4 2020 and has held it in 23 quarters since. The position peaked at $16.2M in Q4 2024. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Charles Schwab held 423,824 shares of Harmony Biosciences worth $15.4M as of Q2 2026.
  • Charles Schwab bought 12,227 Harmony Biosciences shares in Q2 2026, an estimated $386K.
  • Harmony Biosciences made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #1951 holding.
  • Charles Schwab first reported a position in Harmony Biosciences in Q4 2020 and has held it in 23 quarters since.
  • Charles Schwab's Harmony Biosciences position peaked at $16.2M in Q4 2024.
  • 327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.